The Blood-Brain Barrier: Morphology, Physiology and its Changes in Cancer Patients

  • Jean-Yves Delattre
  • Jerome B. Posner
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

It has been clear since the time of Ehrlich that the greater part of the CNS is not stained when Trypan blue is injected into the blood stream, even when other organs of the body are very heavily stained.

Keywords

Toxicity Corticosteroid Morphine Oncol Radionuclide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goldmann EE: Vitalfarbung am Zentralnervensystem. Eimer, Berlin 1913Google Scholar
  2. 2.
    Pardridge WM, Oldendorf WH, Cancilla P, Frank HL: Blood-brain barrier: Interface between internal medicine and the brain. Ann Intern Med 1986 (105):82–95PubMedGoogle Scholar
  3. 3.
    Hauw JJ, Lefauconnier JM: La barrière hématoencéphalique. I-Données morphologiques. Rev Neurol (Paris) 1983 (139):611–624Google Scholar
  4. 4.
    Lefauconnier JM, Hauw JJ: La barrière hématoencéphalique. II-Données physiologiques. Rev Neurol (Paris) 1984 (140):3–13Google Scholar
  5. 5.
    Lefauconnier JM, Hauw JJ: La barrière hématoencéphalique. III-Données physiologiques. Rev Neurol (Paris) 1984 (140):89–109Google Scholar
  6. 6.
    Brightman MW, Klatzo I, Olsson Y, Reese TS: The blood-brain barrier to proteins under normal and pathological conditions. J Neurol Sci 1970 (10):215–239PubMedGoogle Scholar
  7. 7.
    Olsson Y: Vascular permeabilty in the peripheral nervous system. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds) Peripheral Neuropathy, Vol 1. WB Saunders Co, Philadelphia, 1984 pp 579–597Google Scholar
  8. 8.
    Reese TS, Karnovsky MJ: Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967 (34):207–217PubMedGoogle Scholar
  9. 9.
    Sternberger NH, Sternberger LA: Blood-brain barrier protein recognized by monoclonal antibody. Proc Natl Acad Sci 1987 (84):8169–7173PubMedGoogle Scholar
  10. 10.
    Cordon-Cardo C, O’Brien JP, Casals D, Rittman Grauer L, Briedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989 (86):695–698PubMedGoogle Scholar
  11. 11.
    Abott NJ: Glia and the blood-brain barrier. Nature 1987(325):195Google Scholar
  12. 12.
    Stewart PA, Wiley MJ: Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: A study using quail-chick transplantation chimeras. Dev Biol 1981 (84):183–192PubMedGoogle Scholar
  13. 13.
    Janzer RC, Raff MC: Astrocytes induced blood brain barrier properties in endothelial cells. Nature 1987(325):253–257PubMedGoogle Scholar
  14. 14.
    Raichle ME, Hartman BK, Eichling JO, Sharpe LG: Central noradrenergic regulation of cerebral blood flow and vascular permeability. Proc Natl Acad Sci 1975 (72):3726–3730PubMedGoogle Scholar
  15. 15.
    Tengvar C, Petterson CAV, Mohammed AK, Olsson Y: Effects of the noradrenalin neurotoxin N-2 chloroethyl-2-bromo-benzylamine hydrochloride (DSP 4) on the blood-brain barrier: An experimental study in the mouse using protein tracer and density determination techniques. Acta Neuropathol 1979 (78):28–34Google Scholar
  16. 16.
    Harik I: Blood-brain barrier sodium/potassium pump: Modulation by central noradrenergic innervation. Proc Natl Acad Sci USA 1986 (83):4067–4070PubMedGoogle Scholar
  17. 17.
    Estrada C, Hamed E, Krause DN: Biochemical evidence for cholinergic innervation of intracerebral blood vessels. Brain Research 1983 (266):261–270PubMedGoogle Scholar
  18. 18.
    Felgenhauer K: The blood-brain barrier redefined. J Neurol 1986 (233):193–194PubMedGoogle Scholar
  19. 19.
    Broadwell RD, Balin BJ, Salcman M: Transcytotic pathway for blood-borne protein through the blood brain barrier. Proc Natl Acad Sci USA 1988 (85):632–636PubMedGoogle Scholar
  20. 20.
    Bradbury M: The concept of a blood-brain barrier. John Wiley & sons, Chichester 1979Google Scholar
  21. 21.
    Raichle ME, Eichling JO, Grubb RL: Brain permeability of water. Arch Neurol 1974 (30):319–321PubMedGoogle Scholar
  22. 22.
    Walker RW, Cairncross JG, Posner JB: Cerebral herniation in patients receiving cisplatin. J Neuro Oncol 1988 (6):61–65Google Scholar
  23. 23.
    Wasterlain CG, Posner JB: Cerebral edema in water intoxication: I. Clinical and chemical observations. Arch Neurol 1968 (19):71–78PubMedGoogle Scholar
  24. 24.
    Holliday MA, Kalayci MN, Harrah J: Factors that limit brain volume changes in response to acute and sustained hyper and hyponatremia. J Clin Investig 1968 (47):1916–1928PubMedGoogle Scholar
  25. 25.
    Betz AL: Transport of ions across the blood-brain barrier. Federation Proc 1986 (45):2050–2054Google Scholar
  26. 26.
    Harik SI, Gravina SA, Kalaria RN: Glucose transporter of the blood-brain barrier and brain in chronic hyperglycemia. J Neurochem 1988 (51 ):1930–1936PubMedGoogle Scholar
  27. 27.
    Kalaria RN, Gravina SA, Schmidley JW, Perry G, Harik SI: The glucose transporter of the human brain and blood-brain barrier. Ann Neurol 1988 (24)757–764PubMedGoogle Scholar
  28. 28.
    Cremer JE, Ray DE, Sarna GS, Cunningham VJ: A study of the kinetic behaviour of glucose based on simultaneous estimates of influx and phosphorylation in brain regions of rats in different physiological states. Brain Res 1981 (221):331–342PubMedGoogle Scholar
  29. 29.
    Gjedde A, Crone C: Blood-brain glucose transfer: repression in chronic hyperglycemia. Science 1981 (214):456–457PubMedGoogle Scholar
  30. 30.
    Pardridge WM, Choi TB: Neutral amino acid transport at the human blood-brain barrier. Federation Proc 1986 (45):2073–2078Google Scholar
  31. 31.
    Hawkins AR: Transport of essential nutrients across the blood-brain barrier of individual structures. Federation Proc 1986 (45):2055–2059Google Scholar
  32. 32.
    Hargreaves KM, Pardridge WM: Neutral amino acid transport at the blood-brain barrier. J Biol Chem 1988 (263) :19392–19397PubMedGoogle Scholar
  33. 33.
    Rechtand E, Rapoport SI: Regulation of the microenvironment of peripheral nerve: Role of the blood-nerve barrier. Prog Neurobiol 1987 (28):303–343Google Scholar
  34. 34.
    Olsson Y, Reese TS: Inaccessibility of the endoneurium of mouse sciatic nerve to exogenous proteins. Anat Rec 1969 (163):319–325Google Scholar
  35. 35.
    Storm AJ, Van der Kogel AJ, Nooter K: Effect of X-irradiation on the pharmacokinetics of methotrexate ion rats: Alteration of the blood-brain barrier. Eur J Cancer Clin Oncol 1985 (21):759–764PubMedGoogle Scholar
  36. 36.
    Greig NH, Momma S, Sweeney DJ, Smith QR, Rapoport SI: Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 1987 (47):1571–1576PubMedGoogle Scholar
  37. 37.
    Blasberg RG, Groothuis DR, Wright DC, Molnar P: Drug delivery to brain tumors: physiological and pharmacokinetic aspects of chemotherapy. In: Walker MD, Thomas DGT (eds) Biology of Brain tumour. Martinus Nijhoff Publishers, Boston 1986 pp 211–220Google Scholar
  38. 38.
    Groothuis DR, Blasberg RG: Rational brain tumor chemotherapy. The interaction of drug and tumor. Neurol Clinics 1985 (3):801–816Google Scholar
  39. 39.
    Levin VA: Clinical anticancer pharmacology: Some pharmacokinetics considerations. Cancer Treat Rep 1986 (13):61–76Google Scholar
  40. 40.
    Goldstein GW, Betz AL: Blood vessels and the blood-brain barrier. In: Asburry AK, McKhann GM, McDonald Wl (eds) Diseases of the Nervous System. William Heinemann Medical Books, London 1986 pp 172–184Google Scholar
  41. 41.
    Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE: Pharmacokinetics of tumor cell exposure to 14C-methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood tumor barriers in rat brain tumors: A quantitative autoradiographic study. Cancer Res 1988 (48):694–701PubMedGoogle Scholar
  42. 42.
    Hiesiger EM, Basler GA, Lipschutz L, Shapiro WR: Quantitative autoradiographic (QAR) determination of 14C-PCNU concentration in C6 rat glioma after intracarotid administration. Proc Am Ass Cancer Res 1985 (26):349Google Scholar
  43. 43.
    Stillman MJ, Lipschutz L, Sher P, Ohnishi T, Shapiro WR: Pharmacokinetics of 195mPt-cisplatin entry into experimental rat brain tumors as measured by quantitative autoradiography. Proc Am Ass Cancer Res 1986 (27):408Google Scholar
  44. 44.
    Rottenberg DA, Dhawan AJL, Cooper SC, Strother N, Alcock N, Ginos JZ: Assessment of the pharmacologic advantage of intra-arterial versus intravenous chemotherapy using 13N-cisplatin and positron emission tomography: Neurology 1987 (37) Suppl 1: 335Google Scholar
  45. 45.
    Burger PC, Kamenar E, Schold SC, Fay JW, Phillips GL, Herzig GP: Encephalomyelopathy following high-dose BCNU therapy. Cancer 1981 (48):1318–1327Google Scholar
  46. 46.
    Oldendorf WH: A comparison of carotid and venous injection of antitumor agent BCNU. Trans Am Neurol Assoc 1975 (100): 225–226PubMedGoogle Scholar
  47. 47.
    Levin VA, Kabra PM, Freeman-Dove MA: Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 1978 (48):587–593PubMedGoogle Scholar
  48. 48.
    Shapiro WR, Green SB: Re-evaluating the efficacy of intra-arterial BCNU. J Neurosurg 1987 (66):313–315PubMedGoogle Scholar
  49. 49.
    Chan PH, Longar S, Fischman RA: Protective effects of liposome-entrapped superoxide dismutase on posttraumatic brain edema. Ann Neurol 1987 (21):540–547PubMedGoogle Scholar
  50. 50.
    Greer M: Carrier drugs. Neurology 1988 (38):628–632PubMedGoogle Scholar
  51. 51.
    Reulen HJ: Vasogenic brain edema: New aspects in its formation, resolution and therapy. Br J Anaesth 1976 (48):741–752PubMedGoogle Scholar
  52. 52.
    Tengvar C: Extensive intraneuronal spread of horseradish peroxidase from a focus of vasogenic edema into remote areas of central nervous system. Acta Neuropathol 1986 (71):177–189PubMedGoogle Scholar
  53. 53.
    Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF: Quantitative study of microvessel ultrastructure in human peritumoral brain tissue: evidence for a blood-brain barrier defect. J Neurosurg 1987 (67):697–705PubMedGoogle Scholar
  54. 54.
    Vick NA: Brain tumor microvasculature. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastases. GK Hall & Co, Boston 1980 pp 115–133Google Scholar
  55. 55.
    Stewart PA, Hayakawa K, Hayakawa E, Farrell CL, Del Maestro RF: A quantitative study of blood-brain barrier permeability ultrastructure in a new rat glioma model. Acta Neuropathol 1985 (67):96–102PubMedGoogle Scholar
  56. 56.
    Blasberg R, Molnar P, Groothuis D, Patlak C, Owens E, Fenstermacher J: Concurrent measurements of blood flow and transcapillary transport in avian sarcoma virus-induced experimental brain tumors: Implications for chemotherapy. J Pharmacol Exp Therap 1984 (231):724–735Google Scholar
  57. 57.
    Molnar P, Blasberg RG, Horowitz M, Smith B, Fenstermacher J: Regional blood-to-tissue transport in RT-9 brain tumors. J Neurosurg 1983 (58):874–884PubMedGoogle Scholar
  58. 58.
    Levin VA, Freeman-Dove M, Landahl HD: Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 1975 (32):785–791PubMedGoogle Scholar
  59. 59.
    Jarden JO, Dhawan V, Poltorak A, Posner JB, Rottenberg DA: Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of 82Rb : The effect of dexamethasone and whole-brain radiation therapy. Ann Neurol 1985 (18):636–646PubMedGoogle Scholar
  60. 60.
    Dvorak HF: Tumors: wounds that do not heal: Similarities between tumor stroma generation and wound healing. New Engl J Med 1986 (315):1650–1659PubMedGoogle Scholar
  61. 61.
    Ohnishi T, Shapiro WR: Increased capillary in brain produced by a soluble factor from experimental brain tumors: Possible role in cerebral edema. Proc Am Assoc Cancer Res 1987 (28):68Google Scholar
  62. 62.
    Bruce JN, Criscuolo GR, Merrill MJ: Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg 1987 (67):880–884PubMedGoogle Scholar
  63. 63.
    Criscuolo GR, Merrill MJ, Oldfield EH: Further characterization of maligant glioma-derived vascular permeability factor. J Neurosurg 1988 (69):254–262PubMedGoogle Scholar
  64. 64.
    Wahl M, Unterberg A, Baethmann A, Schilling L: Mediators of blood-brain barrier dysfunction and formation of vasogenic edema. J Cereb Blood Flow Metabol 1988 (8):621–634Google Scholar
  65. 65.
    Shapiro WR: A model for brain metastases. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastases. GK Hall & Co, Boston 1980 pp 134–145Google Scholar
  66. 66.
    Ushio Y, Chernik NL, Shapiro WR, Posner JB: Metastatic tumor of the brain: Development of an experimental model. Ann Neurol 1977 (2):20–29PubMedGoogle Scholar
  67. 67.
    Ushio, Posner JB, Shapiro WR: Chemotherapy of experimental meningeal carcinomatosis. Cancer Res 1977 (37):1232–1237PubMedGoogle Scholar
  68. 68.
    Ushio Y, Chernik NL, Posner JB, Shapiro WR: Meningeal carcinomatosis: development of an experimental model. J Neuropathol Exp Neurol 1977(36):224–244Google Scholar
  69. 69.
    Hasegawa H, Allen JC, Mehta BM, Shapiro WR, Posner JB: Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 1979 (29):1280–1286PubMedGoogle Scholar
  70. 70.
    Jaeckle KA, Krol G, Posner JB: Evolution of computed tomographic abnormalities in leptomeningeal metastases. Ann Neurol 1985 (17):85–89PubMedGoogle Scholar
  71. 71.
    Sze G: MRI of tumor metastases to the leptomeninges. MRI Decisions 1988 (2):2–8Google Scholar
  72. 72.
    Ushio Y, Posner R, Posner JB et al: Experimental spinal cord compression caused by epidural neoplasms. Neurology 1977 (27):422–429PubMedGoogle Scholar
  73. 73.
    Delattre J-Y, Arbit E, Thaler HT, Rosenblum MK, Posner JB: A dose-response study of dexamethasone in a model of spinal cord compression caused by epidural tumor. J Neurosurg 1989 (70):920–925PubMedGoogle Scholar
  74. 74.
    Levin VA, Edwards MS, Byrd A: Quantitative observations of the acute effects of x-irradiation on brain capillary permeability. Int J Radiat Oncol Biol Phys 1979 (5):1627–1631PubMedGoogle Scholar
  75. 75.
    Phillips PC, Delattre J-Y, Berger CA, Rottenberg DA: Early and progressive increase in regional brain capillary permeability following single-and fractionated-dose cranial radiation in the rat. Neurology 1987 (37) suppl 1:301Google Scholar
  76. 76.
    Delattre J-Y, Shapiro WR, Posner JB: Acute effects of low-dose cranial irradiation on regional capillary permeability in experimental brain tumors. J Neurol Sciences 1989 (90):147–153Google Scholar
  77. 77.
    Delattre J-Y, Rosenblum MK, Thaler HT, Mandell L, Shapiro WR: A model of radiation myelopathy in the rat: pathology, regional capillary permeability changes and treatment with dexamethasone. Brain 1988 (111):1319–1336PubMedGoogle Scholar
  78. 78.
    Devinsky O, Lemann W, Evans AC, Moeller JR, Rottenberg DA: Akinetic mutism in a bone marrow transplant recipient following total-body irradiation and amphotericin B chemoprophylaxis. A positron emission tomographic and neuropathology study. Arch Neurol 1987 (44):414–417PubMedGoogle Scholar
  79. 79.
    Neuwelt EA, Glasberg M, Frenkel E, Barnett P: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: Neuropathological studies. Ann Neurol 1983 (14):316–324PubMedGoogle Scholar
  80. 80.
    Neuwelt EA, Pagel M, Barnett P, Glassberg M, Frenkel EP: Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier disruption. Cancer Res 1981 (41):4466–4471PubMedGoogle Scholar
  81. 81.
    Neuwelt EA, Barnett PA, Glasberg M, Frenkel EP: Pharmacology and neurotoxicity of cisdiaminedichloroplatinum, bleomycin, 5-fluorouracil and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res1983(43):5278–5285PubMedGoogle Scholar
  82. 82.
    Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP: Effects of adrenal cortical steroids and osmotic blood-brain opening on methotrexate delivery to gliomas in the rodent: The factor of the blood-brain barrier. Proc Natl Acad Sci 1982 (79):4420–4423PubMedGoogle Scholar
  83. 83.
    Tomiwa K, Hazama F, Mikawa H: Neurotoxicity of vincristine after the osmotic opening of the blood brain barrier. J Neuropathol Appl Neurobiol 1983 (9):345–354Google Scholar
  84. 84.
    Phillips PC, Dhawan V, Strother SC, Sidtis JJ, Evans AC, Allen JC, Rottenberg DA: Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: A positron emission tomographic study. Ann Neurol 1987 (21):59–63PubMedGoogle Scholar
  85. 85.
    Hollis PH, Zappulla RA, Spigelman MK, Feuer EJ, Johnson J, Holland JF, Malis LI: Physiological and electrophysiological consequences of etoposide induced blood-brain barrier disruption. Neurosurgery 1986 (18):581–586PubMedGoogle Scholar
  86. 86.
    Spigelman MK, Zapulla RA, Strauchen JA, Feuer EJ, Johnson J, Goldsmith SJ, Malis LI, Holland JF: Etoposide induced blood-brain barrier disruption in rats: Duration of opening and histological sequelae. Cancer Res 1986 (46):1453–1457PubMedGoogle Scholar
  87. 87.
    Alexander JT, Saris SC, Oldfield EH: The effect of interleukin-2 on the blood-brain barrier in the 9L gliosarcoma rat model. J Neurosurg 1989 (70):92–96PubMedGoogle Scholar
  88. 88.
    Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin 2. Neurosurg 1989 (25):202–208Google Scholar
  89. 89.
    Ellison MD, Povlishock, Merchant RE : Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 1987 (47):5765–5770PubMedGoogle Scholar
  90. 90.
    Hedley-White ET, Hsu DW: Effect of dexamethasone on blood-brain barrier in the normal mouse. Ann Neurol 1986 (19):373–377Google Scholar
  91. 91.
    Reid AC, Teasdale GM, McCulloch J: The effects of dexamethasone administration and withdrawal on water permeability across the blood-brain barrier. Ann Neurol 1983 (13):28–31PubMedGoogle Scholar
  92. 92.
    Ziylan YZ, LeFauconnier JM, Bernard G, Bourre JM: Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood-brain barrier. J Neurochem 1988 (51):1338–1342PubMedGoogle Scholar
  93. 93.
    Long JB, Holaday JW: Blood-brain barrier: endogenous modulation by adrenal cortical function. Science 1985 (227):1580–1583PubMedGoogle Scholar
  94. 94.
    Eisenberg HM, Barlow CF, Lorenzo AV: Effect of dexamethasone on altered brain vascular permeability. Arch Neurol 1970 (23):18–22PubMedGoogle Scholar
  95. 95.
    Galicich JH, French LA, Melby JC: Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet 1961 (81):46–53Google Scholar
  96. 96.
    Long DM, Hartmannn JF, French LA: The response of human cerebral edema to glucosteroid administration: An electron microscopic administration. Neurology 1966 (16):521–528PubMedGoogle Scholar
  97. 97.
    Shapiro WR, Posner JB: Corticosteroid hormones: Effects in an experimental brain tumor. Arch Neurol 1974 (30):217–220PubMedGoogle Scholar
  98. 98.
    Yamada K, Bremer AM, West CR: Effects of dexamethasone on tumor-induced brain edema and its distribution in the brain of monkeys. J Neurosurg 1979 (50):361–367PubMedGoogle Scholar
  99. 99.
    Fishman RA: Steroids in the treatment of brain edema. N Engl J Med 1982 (306):359–360PubMedGoogle Scholar
  100. 100.
    Yamata K, Ushio Y, Hayagawa T, Arita N, Yamada N, Mogami H: Effects of methylprednisolone on peritumoral brain edema: A quantitative autoradiographic study. J Neurosurg 1983 (59):612–619Google Scholar
  101. 101.
    Jarden JO, Dhawan V, Moeller JR, Strother SC, Rottenberg DA: The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: A positron emission tomographic study. Ann Neurol 1989 (25):239–245PubMedGoogle Scholar
  102. 102.
    Rapoport SI: Effects of concentrated solution on blood-brain barrier. Am J Physiol 1970 (219):270–274PubMedGoogle Scholar
  103. 103.
    Rapoport SI: Quantitative aspects of osmotic opening of the blood-brain barrier. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastases. GK Hall & Co, Boston 1980 pp 100–114Google Scholar
  104. 104.
    Cosolo WC, Martinello P, Louis WJ, Christophidis N: Blood brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Physiol 1989 (256):R443–R447PubMedGoogle Scholar
  105. 105.
    Koenig H, Goldstone AD, Lu CY, Trout JJ: Polyamines and Ca2+ mediate hyperosmolal opening of the blood-brain barrier: In vitro studies in isolated rat cerebral capillaries. J Neurochem 1989 (52) :1135–1142PubMedGoogle Scholar
  106. 106.
    Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR: Opening the blood brain and blood-tumor barriers in experimental rat brain tumors: The effect of intracarotid hyperosmolar mannitol on capilary permeability and blood flow. Ann Neurol 1986 (19):50–59PubMedGoogle Scholar
  107. 107.
    Warnke PC, Blasberg RG, Groothuis DR: The effect of blood-brain barrier disruption on blood-totissue transport in ENU-induced gliomas. Ann Neurol 1987 (22):300–305PubMedGoogle Scholar
  108. 108.
    Fishman RA: Is there a therapeutic role for osmotic breaching of the blood-brain barrier ? Ann Neurol 1987 (22):300–305Google Scholar
  109. 109.
    Suzuki M, Iwasaki Y, Yamamoto T, Konno H, Kudo H: Sequelae of the osmotic blood-brain barrier opening in rats. J Neurosurg 1988 (69):421–428PubMedGoogle Scholar
  110. 110.
    Neuwelt EA, Specht HD, Hill SA: Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-albumin: Implications for monoclonal antibody therapy. J Neurosurg 1986 (65):194–198PubMedGoogle Scholar
  111. 111.
    Neuwelt EA, Specht D, Barnett PA, Dahlborg SA, Miley A, Larson SM, Brown P, Eckerman KF, Hellström KE, Hellström I: Increased delivery of tumor specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurg 1987 (20):885–895Google Scholar
  112. 112.
    Neuwelt EA, Barnett PA, Hellström I, Hellström KE, Beaumier P, McCormick CI, Weigel RM: Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988 (48):4725–4729PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Jean-Yves Delattre
    • 1
  • Jerome B. Posner
    • 2
  1. 1.Service de NeurologieHôpital de la SalpêtrièreParis Cedex 13France
  2. 2.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations